West LA Times

GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced highlights of an accepted abstract titled, “B7H3-Targeted Tri-specific Killer Engagers deliver IL-15 to NK cells but not T cells, and specifically targets solid tumors as a pan-tumor antigen strategy mediated through NK cells,” for poster presentation both virtually at the European Society for Medical Oncology ("ESMO") Congress 2022 being held at the Paris Expo Porte de Versailles from September 9-13, in Paris, France.

GTB-5550 product candidate is in development for the treatment of B7H3 positive solid tumor cancers and multiple myeloma. GTB-5550 TriKE is a tri-specific molecule composed of a dual camelid nanobody that binds the CD16 receptor on NK cells, the single chain variable fragment (scFv) of an anti-B7H3 antibody, and human IL-15.

Highlights of the abstract poster and mini-oral session include:

• GTB-5550 gives a robust and NK cell specific proliferation signal compared to IL-15 alone
• GTB-5550 specifically targets B7-H3+ cells
• GTB-5550 effectively induced NK cell degranulation and interferon gamma production in response to various prostate, brain tumor (atypical rhabdoid/teratoid), HNSCC, multiple myeloma, sarcoma, ovarian, and myeloid malignancies
• GTB-5550 TriKE In vivo activity in xenogeneic models of human tumor is underway and already validating in vitro studies

“GT Biopharma’s TriKE platform harnesses the natural killing power of NK cells with protein therapeutics, not NK cell therapy. Our approach induces activation of NK cells via CD16 and IL-15 while targeting well-known tumor antigens, offering a potentially safer alternative to T-cell related immunotherapy without cytokine release syndrome and neurotoxicity and we expect to submit an Investigational New Drug (IND) application in 2023 in solid tumors,” said Michael Breen, Executive Chairman and Interim CEO of GT Biopharma.”

Original source can be found here.